The status of cardiac transplantation, 1975.
Since December 1967, 263 human cardiac transplant operations have been performed throughout the world. Eighty-two of these were performed at Stanford University Medical Center, In 1974, 27 such operations were performed, 15 at Stanford Survival rates for the entire Standford series are 48% at one year and 25% at three years; survival rates at one and three years for patients surviving the first three critical months after transplantation are 77% and 42%, respectively. Recipients under the age of 55 years, with New York Heart Association Class IV cardiac disability, are selected for transplant procedures according to criteria dictated by experience over the past seven years. A routine immunsuppressive regimen for organ transplantation, incorporating prednisone, azathioprine, and antithymocyte globulin is employed early postoperatively, and prednisone and azathioprine are used for indefinite maintenance therapy. Acute cardiac graft rejection in nearly all recipients is diagnosed by clinical signs, electrocardiographic changes, and percutaneous transvenous endomyocardial biopsy. Ninety-five percent of acute rejection episodes are reversible with appropriate immunosuppressive treatment, but infectious complications are common and have accounted for 56% of all postoperative deaths. The Stanford experience in cardiac transplantation has demonstrated the potential therapeutic value of this procedure. Maximum survival now extends beyond five years. Satisfactory graft function has been documented in long-term surviving patients, the majority of whom have enjoyed a high degree of social and physical rehabilitation.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D006348:Cardiac Surgical Procedures / Q000401:mortality; D002648:Child; D003327:Coronary Disease / Q000601:surgery; D006084:Graft Rejection / Q000175:diagnosis / Q000188:drug therapy; D006321:Heart / Q000502:physiology; D016027:Heart Transplantation; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology; D011182:Postoperative Care; D011183:Postoperative Complications; D012046:Rehabilitation; D013601:T-Lymphocytes / Q000276:immunology; D014019:Tissue Donors; D014184:Transplantation, Homologous / Q000379:methods / Q000401:mortality
D000961:Antilymphocyte Serum; D008775:Methylprednisolone